TCOV
FOLD

Trust Company of Vermont’s Amicus Therapeutics FOLD Stock Holding History

Trust Company of Vermont’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-70
Closed -$1K – 1026
2019
Q1 		$1K Buy
+70
New +$855 ﹤0.01% 947

Other funds holding FOLD

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Trust Company of Vermont's FOLD Position: Q2 2019 in Review

Trust Company of Vermont sold out of Amicus Therapeutics (FOLD) in Q2 2019, closing a stake of 70 shares — an estimated $1K sold.

Trust Company of Vermont first reported a position in FOLD in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

  • Trust Company of Vermont reported no remaining Amicus Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Trust Company of Vermont sold 70 Amicus Therapeutics shares in Q2 2019, an estimated $1K.
  • Trust Company of Vermont first reported a position in Amicus Therapeutics in Q1 2019 and held it in 1 quarter.
  • Trust Company of Vermont's Amicus Therapeutics position peaked at $1K in Q1 2019.
  • 206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on Trust Company of Vermont's 13F filing for Q2 2019, filed 26 Jul 2019.